Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 77 results for psoriasis

  1. Intravenous infusion of mesenchymal stromal cells in patients with severe recalcitrant psoriasis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  3. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  6. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  10. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA735

  11. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  12. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021

  13. Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    21 July 2021
    View recommendations

    Sections for TA719

  14. What are the cost associated with best supportive care?

    guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details

    Research recommendation
    Published
    16 August 2019

  15. What are the costs associated with best supportive care?

    from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details

    Research recommendation
    Published
    16 August 2019